Company intelligence / Profile preview
Beijing Farber Xintian Pharmaceutical Technology
Zhejiang Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing Farber Xintian Pharmaceutical Technology is a Chinese pharmaceutical company focused on developing small molecules and radiopharmaceutical diagnostic agents for oncology and digestive system diseases. Its lead asset, PMD-11, is in late-stage clinical development for neoplasms. The company has at least one active clinical program and four registered clinical trials as of May 2025. Further details on trial results are not publicly available without registration.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small moleculeRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Beijing Farber Xintian Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Farber Xintian Pharmaceutical Technology.